TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22395265

Group type: EXPERIMENTAL
Intervention: Cycle ergometer warm-up, dynamic stretch component, heavy back squats
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dynamic stretch component
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Heavy back squats
Number of subjects: 16

Group type: COMPARATOR
Intervention: Active warm-up
Number of subjects: 16
Study: 17577032

Group type: EXPERIMENTAL
Intervention: Lomeguatrib (LM) and Temozolomide (TMZ) at doses of 40 to 80 mg LM and 125 mg/m2 TMZ
Number of subjects: 104

Group type: COMPARATOR
Intervention: Temozolomide (TMZ) at a dose of 200 mg/m2
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Lomeguatrib (LM) and Temozolomide (TMZ) after progression on TMZ
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Lomeguatrib (LM) and Temozolomide (TMZ)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Temozolomide (TMZ)
Number of subjects: 104
Study: 14652839

Group type: EXPERIMENTAL
Intervention: First clamping of the proximal aorta
Number of subjects: 40

Group type: COMPARATOR
Intervention: First clamping of the iliac vessels
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Current smokers (sub-group analysis)
Number of subjects: 40
Study: 11450069

Group type: EXPERIMENTAL
Intervention: Neuromuscular Blocking Agents (NBA)
Number of subjects: 427

Group type: COMPARATOR
Intervention: No Neuromuscular Blocking Agents (Control)
Number of subjects: 427
Study: 9349334

Group type: EXPERIMENTAL
Intervention: Topical doxepin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral terfenadine
Number of subjects: 0
Study: 8451599

Group type: EXPERIMENTAL
Intervention: Glucagon infusion (5 ng kg‐1 min‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3534861

Group type: EXPERIMENTAL
Intervention: Dietary sodium restriction for 16 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium repletion for 1 month
Number of subjects: 0
Study: 30882703

Group type: EXPERIMENTAL
Intervention: Huangqi Guizhi Wuwutang granule (HGWG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 29144812

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB; n = 37)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG; n = 33)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Intensive medical therapy (IMT; n = 25)
Number of subjects: 95
Study: 27555205

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 59
Study: 24571582

Group type: EXPERIMENTAL
Intervention: 3 months of leuprolide acetate injections (Group A)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 6 months of leuprolide acetate injections (Group B)
Number of subjects: 56
Study: 21989805

Group type: EXPERIMENTAL
Intervention: Smoking abstinence (24-hour abstinence)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Smoking as usual
Number of subjects: 17
Study: 19462276

Group type: EXPERIMENTAL
Intervention: Folic acid (FNA) 3 mg IV weekly
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Vitamin B12 1 mg IV weekly
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination of folinic acid and vitamin B12 IV weekly
Number of subjects: 75
Study: 18004136

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14690657

Group type: EXPERIMENTAL
Intervention: Distolingual alveolectomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tooth division technique
Number of subjects: 120
Study: 12205258

Group type: EXPERIMENTAL
Intervention: Iron supplements
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study: 9586208

Group type: EXPERIMENTAL
Intervention: Belief group (trained on false belief tasks)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Picture group (trained on false picture tasks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (trained on number conservation tasks)
Number of subjects: 67
Study: 7707099

Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride 10 mg orally
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride 10 mg rectally
Number of subjects: 34
Study: 2576257

Group type: EXPERIMENTAL
Intervention: GTD + EE (50 micrograms GTD + 30 micrograms EE for 6 days, 70 micrograms GTD + 40 micrograms EE for 5 days, and 100 micrograms GTD + 30 micrograms EE for 10 days)
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: GTD + EE
Number of subjects: 639

Group type: COMPARATOR
Intervention: NET + EE
Number of subjects: 639

Group type: COMPARATOR
Intervention: DSG + EE
Number of subjects: 639

Group type: COMPARATOR
Intervention: All OCs
Number of subjects: 639
Study: 780062

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (oral solution)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin (buccal tablets)
Number of subjects: 100
Study: 30277102

Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus CHOP (G-CHOP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Shorter duration of infusion (SDI) of obinutuzumab
Number of subjects: 100
Study: 28841632

Group type: EXPERIMENTAL
Intervention: Usual care sedation regimen
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Greater than or equal to 3 DSM-5 symptoms (75th percentile)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Greater than or equal to 4 Bush Francis Catatonia Screening Instrument items
Number of subjects: 136
Study: 26744887

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 40
Study: 23920083

Group type: EXPERIMENTAL
Intervention: PlGF (placental growth factor)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: sFlt‐1 (soluble fms‐like tyrosine kinase 1)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: sEng (soluble endoglin)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Ratio of PlGF to sEng
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Ratio of sFlt‐1 to PlGF
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Logistic model with established risk factors + ratio of PlGF to sEng
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Logistic model with established risk factors + ratio of sFlt‐1 to PlGF
Number of subjects: 540
Study: 21121874

Group type: EXPERIMENTAL
Intervention: omalizumab (75-375 mg sc, q2 or q4 wk)
Number of subjects: 926

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 926
Study: 18809182

Group type: EXPERIMENTAL
Intervention: Conceptual sequencing of practice problems
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Well-structured procedural practice
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Initial procedural skills
Number of subjects: 72
Study: 17491173

Group type: EXPERIMENTAL
Intervention: NOT Plus (Web-based adjunct)
Number of subjects: 29

Group type: COMPARATOR
Intervention: NOT (group-based program)
Number of subjects: 29
Study: 15307288

Group type: EXPERIMENTAL
Intervention: Magnetostimulation with weak variable magnetic field (15 microT) for 12 minutes daily for 15 days added to pharmacological therapy.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham exposure with the same device (no active magnetostimulation).
Number of subjects: 24
Study: 11713611

Group type: EXPERIMENTAL
Intervention: Buspirone (0.5 mg x kg bw(‐1) orally)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Buspirone with pindolol pre‐treatment (40 mg over 2 days, 0.5 mg x kg bw(‐1) on test day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Pindolol alone (40 mg over 2 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo with pindolol pre‐treatment
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 35
Study: 9263712

Group type: EXPERIMENTAL
Intervention: Endometrial ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 0
Study: 7708406

Group type: EXPERIMENTAL
Intervention: Peripheral electrical stimulation at 20 mA
Number of subjects: 36
Study: 2439677

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 51

Group type: COMPARATOR
Intervention: Silk sutures
Number of subjects: 51
Study: 30676202

Group type: EXPERIMENTAL
Intervention: Ulnar-based orthotics
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ulnar-based orthotics plus strengthening exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 30
Study: 29959306

Group type: EXPERIMENTAL
Intervention: 4% articaine with epinephrine (1:200,000)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2% lidocaine with epinephrine (1:200,000)
Number of subjects: 20
Study: 26901590

Group type: EXPERIMENTAL
Intervention: Stress imagery session followed by a contingency management-based relapse analogue paradigm
Number of subjects: 26
Study: 24622804

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (2000 IU oral vitamin D3/d)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 218
Study: 22435438

Group type: EXPERIMENTAL
Intervention: Griseofulvin
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study: 20083429

Group type: EXPERIMENTAL
Intervention: Standard CPAP titration during polysomnography (PSG)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ambulatory titration using auto‐CPAP and home sleep testing
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both PSG and ambulatory groups
Number of subjects: 61

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 61
Study: 18812608

Group type: EXPERIMENTAL
Intervention: BI 1356 (2.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 1356 (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 1356 (100 mg to 600 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BI 1356 (600 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16398901

Group type: EXPERIMENTAL
Intervention: Education session for nurses and provision of three hip protectors per resident
Number of subjects: 942

Group type: COMPARATOR
Intervention: Control group care optimized by providing brief information and two protectors per nursing home
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Intervention program
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Sensitivity analyses for real practice implementation
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Intervention program with lower hip protector reimbursement levels
Number of subjects: 942
Study: 14703265

Group type: EXPERIMENTAL
Intervention: Trained paraprofessional advocates working one-on-one with women for 10 weeks
Number of subjects: 278

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 278
Study: 10832003

Group type: EXPERIMENTAL
Intervention: Verbal delayed reaction methodology with a 1.5-s foreperiod
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Verbal delayed reaction methodology with a 0.1-s foreperiod
Number of subjects: 18

Group type: COMPARATOR
Intervention: Verbal delayed reaction methodology
Number of subjects: 18
Study: 8826808

Group type: EXPERIMENTAL
Intervention: Buffy-coat poor blood
Number of subjects: 589

Group type: COMPARATOR
Intervention: Leucocyte-depleted blood
Number of subjects: 589
Study: 1467719

Group type: EXPERIMENTAL
Intervention: Unstructured paper questionnaire
Number of subjects: 2424

Group type: EXPERIMENTAL
Intervention: Structured paper questionnaire
Number of subjects: 2424

Group type: EXPERIMENTAL
Intervention: Computerised questionnaire
Number of subjects: 2424
Study: 6423016

Group type: EXPERIMENTAL
Intervention: Capsaicin inhalation (2-65 mumol l(-1), 1 min duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium cromoglycate inhalation
Number of subjects: 0
Study: 31120846

Group type: EXPERIMENTAL
Intervention: Metacognitive strategy training (n = 21)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Direct skill training (n = 22)
Number of subjects: 43
Study: 28184420

Group type: EXPERIMENTAL
Intervention: Treatment arms
Number of subjects: 2155

Group type: COMPARATOR
Intervention: Placebo arms
Number of subjects: 2155
Study: 25462877

Group type: EXPERIMENTAL
Intervention: Enhanced cognitive behavior therapy (CBT-E)
Number of subjects: 43
Study: 23270535

Group type: EXPERIMENTAL
Intervention: Exercise intervention (two different doses)
Number of subjects: 112

Group type: COMPARATOR
Intervention: No-exercise control group
Number of subjects: 112
Study: 21740239

Group type: EXPERIMENTAL
Intervention: Sectional matrix (Standard matrix, Palodent) with wedge and separation ring (BiTine I)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sectional matrix with separation rings at both mesial and distal sides (BiTine I+II)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Walser matrix (O-form)
Number of subjects: 45
Study: 19249933

Group type: EXPERIMENTAL
Intervention: Cooling cap (Discrete Cerebral Hypothermia System) for 24 hours, then rewarmed over 24 hours.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no cooling cap).
Number of subjects: 25
Study: 16752240

Group type: EXPERIMENTAL
Intervention: Distension of pelvic structures
Number of subjects: 50

Group type: COMPARATOR
Intervention: Counseling (Control)
Number of subjects: 50
Study: 12059825

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Uncuffed tracheal tube
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both devices
Number of subjects: 20
Study: 10512899

Group type: EXPERIMENTAL
Intervention: Good functional outcome (Barthel Index >/=50 points)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Poor functional outcome (Barthel Index <50 points)
Number of subjects: 223
Study: 7552558

Group type: EXPERIMENTAL
Intervention: Assertive community treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-quality case management
Number of subjects: 0
Study: 2032101

Group type: EXPERIMENTAL
Intervention: Hand sewn ileoanal anastomosis with mucosectomy (group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Stapled ileoanal anastomosis without mucosectomy (group B)
Number of subjects: 32
Study: 6459547

Group type: EXPERIMENTAL
Intervention: 5 percent IDU in DMSO
Number of subjects: 46

Group type: COMPARATOR
Intervention: DMSO alone
Number of subjects: 46
Study: 6403323

Group type: EXPERIMENTAL
Intervention: 2 mg ergotamine tartrate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6 mg ergotamine tartrate
Number of subjects: 20
Study: 30169665

Group type: EXPERIMENTAL
Intervention: Intensive intervention (IPC + CM + MM)
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Nonintensive intervention (standard nutrition counseling + less intensive CM and MM)
Number of subjects: 2400
Study: 26423213

Group type: EXPERIMENTAL
Intervention: Anomalous evidence (varying amounts)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Convergent evidence (multiple types)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presentation of an alternative theory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anomalous evidence (replicating)
Number of subjects: 0
Study: 24836213

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily for three months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo daily for three months
Number of subjects: 0
Study: 22964973

Group type: EXPERIMENTAL
Intervention: 2-fold illumination (20 and 80 J/cm2)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Single illumination (75 J/cm2)
Number of subjects: 247
Study: 20424458

Group type: EXPERIMENTAL
Intervention: Naltrexone implants
Number of subjects: 46

Group type: COMPARATOR
Intervention: Methadone treatment
Number of subjects: 46
Study: 18418029

Group type: EXPERIMENTAL
Intervention: Desloratadine (standard dose) during association phase
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water (placebo) during evocation trial
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Novel-tasting drink with placebo pill (CS group) during evocation trial
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Water with desloratadine (drug group) during evocation trial
Number of subjects: 30
Study: 16000277

Group type: EXPERIMENTAL
Intervention: Dipyridamole-induced ischemic ECG changes
Number of subjects: 629

Group type: COMPARATOR
Intervention: Nonischemic ECG group
Number of subjects: 629
Study: 12888045

Group type: EXPERIMENTAL
Intervention: Topical betaxolol (twice daily)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 10595045

Group type: EXPERIMENTAL
Intervention: Five-minute foot massage
Number of subjects: 25
Study: 8917061

Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 300 mg twice daily for 14 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 10
Study: 1869343

Group type: EXPERIMENTAL
Intervention: 25 mg diphenhydramine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 20
Study: 7165555

Group type: EXPERIMENTAL
Intervention: Acetate dialysis
Number of subjects: 7

Group type: COMPARATOR
Intervention: Bicarbonate dialysis
Number of subjects: 7
Study: 31015317

Group type: EXPERIMENTAL
Intervention: Patient-Oncologist dyads
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Caregiver-Oncologist dyads
Number of subjects: 581

Group type: COMPARATOR
Intervention: Oncologist practice duration
Number of subjects: 581

Group type: COMPARATOR
Intervention: Patient ethnicity
Number of subjects: 581

Group type: COMPARATOR
Intervention: Cancer type
Number of subjects: 581

Group type: COMPARATOR
Intervention: Caregiver ethnicity
Number of subjects: 581

Group type: COMPARATOR
Intervention: Caregiver physical health
Number of subjects: 581

Group type: COMPARATOR
Intervention: Caregiver income and anxiety
Number of subjects: 581
Study: 30059552

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise training for 16 weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (original exercise mode unchanged)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise training
Number of subjects: 134
Study: 26998485

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser plus topical application of Botulinum Toxin Type A (BTX‐A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fractional CO2 plus saline solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both treatments (BTX‐A and saline solution)
Number of subjects: 20
Study: 24517309

Group type: EXPERIMENTAL
Intervention: Gastric bypass (Bypass)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gastric band (Band)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 0
Study: 22971260

Group type: EXPERIMENTAL
Intervention: Trainer for Kids™
Number of subjects: 54

Group type: COMPARATOR
Intervention: modified Activator
Number of subjects: 54
Study: 20176212

Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sham (circulation without an interposed filter)
Number of subjects: 65
Study: 17413119

Group type: EXPERIMENTAL
Intervention: 10.5 g P. ovata husk/d
Number of subjects: 28

Group type: COMPARATOR
Intervention: 10.5 g P. ovata seeds/d
Number of subjects: 28
Study: 16229653

Group type: EXPERIMENTAL
Intervention: Bispectral fluorescence imaging combined with texture analysis and Fisher linear discrimination (FLD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cross validation of the training set
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contrast feature from co-occurrence matrices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neighborhood average features of autofluorescence and Pp IX fluorescence
Number of subjects: 0
Study: 12882179

Group type: EXPERIMENTAL
Intervention: In-bed scales
Number of subjects: 2

Group type: COMPARATOR
Intervention: Freestanding scales
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Weights over 1,500 g
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Weights < 1,500 g
Number of subjects: 2
Study: 9973031

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 7588510

Group type: EXPERIMENTAL
Intervention: High-fibre diet based on oat bran (31.9 g/day fibre)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-fibre diet based on wheat flour (7.8 g/day fibre)
Number of subjects: 10
Study: 2372469

Group type: EXPERIMENTAL
Intervention: Iopentol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 12
Study: 6999828

Group type: EXPERIMENTAL
Intervention: Ketocaine compresses (1 g ketocaine in a 10% ethanol solution)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo compresses (without ketocaine)
Number of subjects: 23
Study: 31615445

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 270

Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 270
Study: 28404531

Group type: EXPERIMENTAL
Intervention: PC + EC group (n = 47)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: PC group (n = 56)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: EC group (n = 49)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Conventional guide group (n = 62)
Number of subjects: 214
Study: 25742716

Group type: EXPERIMENTAL
Intervention: Standard-dose GH treatment (33 μg kg(‐1) day(‐1))
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Double-dose treatment (67 μg kg(‐1) day(‐1))
Number of subjects: 167

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 167
Study: 24340313

Group type: EXPERIMENTAL
Intervention: Instructional video
Number of subjects: 133

Group type: COMPARATOR
Intervention: Nonvideo group
Number of subjects: 133
Study: 21638184

Group type: COMPARATOR
Intervention: Paradoxical image
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Digitally flipped image (mirror-image)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Inverted image
Number of subjects: 61
Study: 19798097

Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg daily
Number of subjects: 5665

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5665

Group type: EXPERIMENTAL
Intervention: BP lowering across 10 trials
Number of subjects: 5665

Group type: EXPERIMENTAL
Intervention: Diuretics as component of therapy
Number of subjects: 5665

Group type: EXPERIMENTAL
Intervention: Renin system inhibitors
Number of subjects: 5665